Market News & Trends
Ocugen, Inc. Announces Submission of IND to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate
Ocugen, Inc. recently announced that it has submitted an Investigational New Drug application (IND) with the US FDA to evaluate the COVID-19 vaccine….
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. recently announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy….
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
Halberd Corporation recently announced the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood…
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA (pembrolizumab) in Patients With Melanoma
Evaxion Biotech A/S recently announced it has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ,…
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement With Bristol Myers Squibb
TCR2 Therapeutics Inc. recently announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo (nivolumab) and Yervoy (ipilimumab)…
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy & Powerful Potential of Antigen-Independent Tumor Targeting
Cybrexa Therapeutics recently announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex-exatecan). The initial data show robust….
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. recently announced the last participant has completed the 26-week dosing period and 30-day safety follow up visit in the GEM-3 study, Krystal’s…
Berkeley Lights Announces GSK Acquires Third Beacon Optofluidic System to Expand Antibody Therapeutics Development
Berkeley Lights, Inc. recently announced GlaxoSmithKline (GSK) has purchased an additional Beacon Optofluidic system to expand its antibody therapeutics capacity. The new Beacon system will….
Catalent's Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus Increases to $360 Million
Catalent recently announced a $230-million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene…
Micropore Appoints New Commercial Director
UK-based Micropore Technologies has recently appointed Denis Smit, Invista’s former Head of New Business Development, to the role of Commercial Director to lead their….
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever System in Pulmonary Embolism Patients
Inari Medical, Inc. recently announced planned enrollment of the PEERLESS trial. PEERLESS is a new randomized controlled trial (RCT) comparing the clinical outcomes of patients with intermediate-high risk pulmonary embolism….
Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform
Quris recently launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans – significantly improving efficacy and cutting drug development….
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Phathom Pharmaceuticals, Inc. recently announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal Phase 3 trial evaluating….
Menarini Group & Radius Health Announce Positive Phase 3 Topline Results From the EMERALD Trial Evaluating Elacestrant in Breast Cancer
The Menarini Group and Radius Health, Inc. recently announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a….
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Athira Pharma, Inc. recently announced it has completed enrollment in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease.…
HistoWiz Raises $32-Million Financing to Fully Automate Lab Operations, Launch New AI-Enabled Services & Establish a GLP Histopathology Lab in Miami
HistoWiz, a leading digital histopathology service company, recently announced the closing of a $32-million Series A financing. The company has provided automated histology for over…
Interpace Diagnostics Announces US Patent Approval: MicroRNAs as Biomarkers for Distinguishing Benign From Malignant Thyroid Neoplasms
Interpace Biosciences, Inc. recently announced the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231 B2) for use of microRNAs…
MatriSys Announces Positive Results from a Study of S. felis for the Treatment of Drug-Resistant S. pseudintermedius
MatriSys Bioscience recently announced the publication of research on a strain of Staphylococcus felis (S. felis C4) isolated from feline skin for the treatment of Methicillin-resistant…
reMYND’s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer’s, Has Moved to MAD Phase After Demonstrating Strong Safety in SAD Phase
reMYND NV recently announce it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in…
Pfizer & BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Pfizer Inc. and BioNTech SE recently announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of…
